← Back to Search

Behavioural Intervention

Cognitive Dysfunction Interventions for Long COVID

N/A
Waitlist Available
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization
≥ 18 years of age at the time of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, eoi (day 70), eos (day 160)
Awards & highlights

Study Summary

This trial is designed to evaluate interventions for cognitive decline due to PASC, and can be used in different settings to help people with COVID-19 related cognitive issues.

Who is the study for?
Adults over 18 who've had cognitive issues for at least 12 weeks after COVID-19, scoring below 40 on a cognitive test. They must have had symptoms like fever and cough or been in contact with a confirmed case. Participants need to speak English or Spanish and can't be using certain drugs for neurological conditions, substance abuse disorders, or other clinical trials.Check my eligibility
What is being tested?
The trial is testing different treatments for long-term cognitive problems after COVID-19. It includes active tDCS (a brain stimulation technique), sham tDCS (placebo), BrainHQ exercises, and PASC CoRE activities. The study randomly assigns participants to these interventions to see which helps improve attention and executive function.See study design
What are the potential side effects?
tDCS may cause mild side effects like itching, tingling, headache, fatigue during application; BrainHQ exercises are non-invasive but could lead to mental fatigue due to the nature of cognitive tasks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had COVID-19 before.
Select...
I am 18 years old or older.
Select...
I have symptoms like fever and cough or have been in contact with someone with COVID-19.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, eoi (day 70), eos (day 160)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, eoi (day 70), eos (day 160) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Change in Everyday Cognition 2 (ECog2)
Change in PROMIS-cognitive function - short form 8a (PROMIS-Cog) total score
Change on an objective neurocognitive battery scores
+1 more

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: BrainHQ + PASC CoREExperimental Treatment2 Interventions
BrainHQ plus 9 group sessions at 1.5 hr/session and 3 individual sessions at 1 hr/session
Group II: BrainHQExperimental Treatment1 Intervention
5 sessions/week at 30 min/session
Group III: Brain HQ + tDCS-activeExperimental Treatment2 Interventions
2.0 mA stimulation delivered for 30 min during each BrainHQ session
Group IV: BrainHQ Active ComparatorActive Control1 Intervention
5 sessions/week at 30 min/session
Group V: Brain HQ + tDCS-shamPlacebo Group2 Interventions
Inactive stimulation delivered for 30 min during each BrainHQ session

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,358 Previous Clinical Trials
3,419,754 Total Patients Enrolled
Daniel Laskowitz, MD MHSStudy ChairDuke University
1 Previous Clinical Trials
315 Total Patients Enrolled
Kanecia Zimmerman, MD PhDStudy ChairDuke University
2 Previous Clinical Trials
1,215 Total Patients Enrolled

Media Library

BrainHQ (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05965752 — N/A
Long COVID Syndrome Research Study Groups: BrainHQ Active Comparator, BrainHQ, BrainHQ + PASC CoRE, Brain HQ + tDCS-active, Brain HQ + tDCS-sham
Long COVID Syndrome Clinical Trial 2023: BrainHQ Highlights & Side Effects. Trial Name: NCT05965752 — N/A
BrainHQ (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05965752 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment for this experiment still open?

"Per the information available on clinicaltrials.gov, this medical trial is currently not recruiting patients; its first post date was July 1st 2023 and it has most recently been edited July 25th of the same year. Nevertheless, there are 1336 other clinical studies in search of participants presently."

Answered by AI

Who else is applying?

What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

I'm desperate and have had cocid 4 times before August of 2021 and doctors didn't believe me.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
2023. "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05965752.
All > Survivor Corps
~121 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top